# A Trial of SHR-1701 in Combination With Gemcitabine and Albumin Paclitaxel in Patients With Pancreatic Cancer

> **NCT04624217** · PHASE1,PHASE2 · COMPLETED · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 56 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** SHR-1701

## Key facts

- **NCT ID:** NCT04624217
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-24
- **Primary completion:** 2021-09-16
- **Final completion:** 2023-02-08
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2024-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04624217

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04624217, "A Trial of SHR-1701 in Combination With Gemcitabine and Albumin Paclitaxel in Patients With Pancreatic Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04624217. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*